Bridgeway Capital Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Bridgeway Capital Management’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,265	Closed	-$19K	–	1478
2023 Q1	$19K	Hold	5,265	–	–	﹤0.01%	1357
2022 Q4	$170K	Hold	5,265	–	–	﹤0.01%	1124
2022 Q3	$220K	Buy	+5,265	New	+$241K	0.01%	1124
2020 Q3	–	Sell	-3,425	Closed	-$336K	–	1373
2020 Q2	$336K	Sell	3,425 -3,250	-49%	-$284K	0.01%	1007
2020 Q1	$501K	Hold	6,675	–	–	0.01%	760
2019 Q4	$542K	Buy	+6,675	New	+$747K	0.01%	950

Other funds holding EVLO

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgeway Capital Management's EVLO Position: Q2 2023 in Review

Bridgeway Capital Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2023, closing a stake of 5,265 shares — an estimated $19K sold.

Bridgeway Capital Management first reported a position in EVLO in Q4 2019 and held it in 6 quarters. The position peaked at $542K in Q4 2019. 25 funds tracked by Wall St. Rank hold EVLO as of Q2 2023.

Bridgeway Capital Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Bridgeway Capital Management sold 5,265 Evelo Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $19K.
Bridgeway Capital Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q4 2019 and held it in 6 quarters.
Bridgeway Capital Management's Evelo Biosciences, Inc. Common Stock position peaked at $542K in Q4 2019.
25 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.